Mitigation of off-target adrenergic binding and effects on cardiovascular function in the discovery of novel ribosomal S6 kinase 2 inhibitors

Journal of Pharmacology and Experimental Therapeutics

Volumn 340, Issue 3, 2012, Pages 492-500

  Fryer, Ryan M ^a   Muthukumarana, Akalushi ^a   Chen, Rong Rhonda ^a   Smith, James D ^a   Mazurek, Suzanne Nodop ^a   Harrington, Kyle E ^a   Dinallo, Roger M ^a   Burke, Jennifer ^a   DiCapua, Frank M ^a   Guo, Xin ^a   Kirrane, Thomas M ^a   Snow, Roger J ^a   Zhang, Yunlong ^a   Soleymanzadeh, Fariba ^a   Madwed, Jeffrey B ^a   Kashem, Mohammed A ^a   Kugler, Stanley Z ^a   O'Neill, Margaret M ^a   Harrison, Paul C ^a   Reinhart, Glenn A ^a   Boyer, Stephen J ^a   more..

^a BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 METHYL 1 OXO 2,3,4,5 TETRAHYDRO 1H [1,4]DIAZEPINOL[1,2 A]INDOLE 8 CARBOXYLIC ACID [ 1 (3 DIMETHYLAMINOPROPYL) 1H BENZOIMIDAZOL 2 YL]AMIDE; ALPHA 1 ADRENERGIC RECEPTOR; ALPHA 2 ADRENERGIC RECEPTOR; BIX 02565; CARDIOVASCULAR AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BLOOD VESSEL TONE; CARDIOVASCULAR EFFECT; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TARGETING; HEART RATE VARIABILITY; HIGH THROUGHPUT SCREENING; IN VITRO STUDY; IN VIVO STUDY; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; AZEPINES; BENZIMIDAZOLES; BLOOD PRESSURE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DISCOVERY; MALE; PROTEIN KINASE INHIBITORS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ADRENERGIC, ALPHA-1; RECEPTORS, ADRENERGIC, ALPHA-2; RIBOSOMAL PROTEIN S6 KINASES, 90-KDA;

EID: 84863143307     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.111.189365     Document Type: Article

References (21)

1. Adams HR (1984) New perspectives in cardiopulmonary therapeutics: receptorselective adrenergic drugs. J Am Vet Med Assoc 185:966-974.
2. Avkiran M, Cook AR, and Cuello F (2008) Targeting Na+/H+ exchanger regulation for cardiac protection: a RSKy approach? Curr Opin Pharmacol 8:133-140.
3. Banfor PN, Franklin PA, Segreti JA, Widomski DL, Davidsen SK, Albert DH, Cox BF, Fryer RM, and Gintant GA (2009) ETA receptor blockade with atrasentan prevents hypertension with the multitargeted tyrosine kinase inhibitor ABT-869 in telemetry-instrumented rats. J Cardiovasc Pharmacol 53:173-178.
4. Boyer SJ, Gao AD, Guo X, Kirrane TM, Sarko CR, Snow RJ, Soleymanzadeh F, and Zhang Y (2011) Heterocyclic Compounds Containing an Indole Core. World Patent WO2011/071716A1. 16 Jun 2011.
5. Cole RT, Kalogeropoulos AP, Georgiopoulou VV, Gheorghiade M, Quyyumi A, Yancy C, and Butler J (2011) Hydralazine and isosorbide dinitrate in heart failure: historical perspective, mechanisms, and future directions. Circulation 123:2414-2422.
6. Franklin PH, Banfor PN, Tapang P, Segreti JA, Widomski DL, Larson KJ, Noonan WT, Gintant GA, Davidsen SK, Albert DH, et al. (2009) Effect of the multitargeted receptor tyrosine kinase inhibitor, ABT-869 [N-(4-(3-amino-1H- indazol-4- yl)phenyl)-N′-(2-fluoro-5-methylphenyl)urea], on blood pressure in conscious rats and mice: reversal with antihypertensive agents and effect on tumor growth inhibition. J Pharmacol Exp Ther 329:928-937.
7. Gerc V and Buksa M (2010) Advantages of renin-angiotensin system blockade in the treatment of cardiovascular diseases. Med Arh 64:295-299.
8. Ghali JK, Tam SW, Ferdinand KC, Lindenfeld J, Sabolinski ML, Taylor AL, Worcel M, Curry CL, Cohn JN, and A-HeFT Investigators (2007) Effects of ACE inhibitors or beta-blockers in patients treated with the fixed-dose combination of isosorbide dinitrate/hydralazine in the African-American Heart Failure Trial. Am J Cardiovasc Drugs 7:373-380. (Pubitemid 47624541)
9. Honore P, Chandran P, Hernandez G, Gauvin DM, Mikusa JP, Zhong C, Joshi SK, Ghilardi JR, Sevcik MA, Fryer RM, et al. (2009) Repeated dosing of ABT-102, a potent and selective TRPV1 antagonist, enhances TRPV1-mediated analgesic activity in rodents, but attenuates antagonist-induced hyperthermia. Pain 142:27-35.
10. Karmazyn M (2001) Therapeutic potential of Na-H exchange inhibitors for the treatment of heart failure. Expert Opin Investig Drugs 10:835-843.
11. Karmazyn M, Sawyer M, and Fliegel L (2005) The Na(+)/H(+) exchanger: a target for cardiac therapeutic intervention. Curr Drug Targets Cardiovasc Haematol Disord 5:323-335. (Pubitemid 41131703)
12. Karmazyn M, Sostaric JV, and Gan XT (2001) The myocardial Na+/H+ exchanger: a potential therapeutic target for the prevention of myocardial ischaemic and reperfusion injury and attenuation of postinfarction heart failure. Drugs 61:375-389. (Pubitemid 32270046)
13. Khwanchuea R, Mulvany MJ, and Jansakul C (2008) Cardiovascular effects of tyramine: adrenergic and cholinergic interactions. Eur J Pharmacol 579:308-317.
14. Kirrane TM, Boyer SJ, Burke J, Guo X, Snow RJ, Soleymanzadeh L, Swinamer A, Zhang Y, Madwed JB, Kashem M, et al. (2011) Indole RSK inhibitors. Part 2: Optimization of cell potency and kinase selectivity. Bioorg Med Chem Lett doi: 10.1016/j.bmcl.2011.10.029.
15. Kym PR, Souers AJ, Campbell TJ, Lynch JK, Judd AS, Iyengar R, Vasudevan A, Gao J, Freeman JC, Wodka D, et al. (2006) Screening for cardiovascular safety: a structure-activity approach for guiding lead selection of melanin concentrating hormone receptor 1 antagonists. J Med Chem 49:2339-2352.
16. 2+ clocks and surface membrane voltage clocks controls the timekeeping mechanism of the heart's pacemaker. Circ Res 106:659-673.
17. Langer SZ and Schoemaker H (1989) Alpha-adrenoceptor subtypes in blood vessels: physiology and pharmacology. Clin Exp Hypertens A 11 (Suppl 1):21-30. (Pubitemid 19159106)
18. Luft FC, Veelken R, Becker H, Ganten D, Lang RE, and Unger T (1986) Effect of urapidil, clonidine, and prazosin on sympathetic tone in conscious rats. Hypertension 8:303-311. (Pubitemid 16042199)
19. McDevitt DG (1989) In vivo studies on the function of cardiac beta-adrenoceptors in man. Eur Heart J 10 (Suppl B):22-28.
20. Prakash C, Chen W, Rossulek M, Johnson K, Zhang C, O'Connell T, Potchoiba M, and Dalvie D (2008) Metabolism, pharmacokinetics, and excretion of a cholesteryl ester transfer protein inhibitor, torcetrapib, in rats, monkeys, and mice: characterization of unusual and novel metabolites by high-resolution liquid chromatography-tandem mass spectrometry and 1H nuclear magnetic resonance. Drug Metab Dispos 36:2064-2079.
21. Wasson S, Fleming D, and Reddy HK (2005) Evidence-based drug treatment of heart failure. Mo Med 102:540-548;quiz 548-549.